A New Day Begins With SPRAVATO

The first and only NMDA receptor antagonist approved for TRD in adults

SPRAVATO™ hypothesized mechanism of action

SPRAVATO™ clinical program overview

Studied in more than 1700 adult patients with treatment-resistant depression1

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS1,2

COMPARED TO PLACEBO NASAL SPRAY + ORAL AD1

References:

1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.

2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.

Indication:

SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.

SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO™ as an anesthetic agent have not been established.

Use The Link Below To Learn More About Important Safety Information...

© 2019 Charak Center for Health and Wellness. All Rights Reserved.